Citi Pharma Expands with Pakheim Acquisition
Summary
Citi Pharma acquires Pakheim to boost manufacturing and market presence, targeting Rs 5B revenue in five years.
Kind of disclosure: Expansion/Capex
Read the original filingKey facts
- Acquisition of Pakheim International Pharmaceuticals
- 100% shareholding
- Current annual revenue of acquired business
- Rs 500M
- Targeted revenue over the next five years
- Rs 5B
- Regulatory approvals pending
- Necessary for transaction completion
- Payment plan completion
- 2026-12-31
Citi Pharma Ltd. (CPHL) on Nafa
Last price Rs 64.00 · Pharmaceuticals · You can own CPHL shares from your phone.
More CPHL announcements
- NoticeTransmission of Quarterly Report for the Period Ended 30 September 2026
- Financial resultCiti Pharma Limited reported a net profit of Rs 233.23 million for the period ended September 30, 2026Filed as: Financial Results for the Quarter Ended 30 September 2026
- NoticeBoard Meeting In Progress
- Material informationCiti Pharma Acquires 20% of Pakheim InternationalCiti Pharma Limited acquires 20% shareholding in Pakheim International Pharma, marking the first step towards full acquisition.
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeChange of Chief Financial Officer
Source: Citi Pharma Ltd.'s filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.